HIF-EPO-Iron
(Unterschied zwischen Versionen)
Ossip Groth (Diskussion | Beiträge)
(Die Seite wurde neu angelegt: „ '''HIF1''' {{tp|p=32464493|t=2020. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.|pdf=|usr=009}} '''Erythropoietin''' {{tp|p=32270515|t=…“)
Zum nächsten Versionsunterschied →
(Die Seite wurde neu angelegt: „ '''HIF1''' {{tp|p=32464493|t=2020. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.|pdf=|usr=009}} '''Erythropoietin''' {{tp|p=32270515|t=…“)
Zum nächsten Versionsunterschied →
Version vom 7. Juli 2020, 15:46 Uhr
HIF1
32464493 2020. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.
Erythropoietin
32270515 2020. Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?
32479920 2020. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19.
32534130 2020. EPO in Patients With COVID-19: More Than an Erythropoietic Hormone.
Iron chelators
32418885 2020. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?
